Get startedLog in
    Picture of Shanghai Junshi Biosciences logo

    1877 — Shanghai Junshi Biosciences News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapSucker Stock
    All News

    Brief: Shanghai Junshi Biosciences Says Phase 3 Clinical Study Of Toripalimab In Combination With Bevacizumab Met Primary Endpoint

    Picture of Shanghai Junshi Biosciences logoShanghai Junshi Biosciences
    11/06/2024 16:25
    June 11 (Reuters) - Shanghai Junshi Biosciences Co Ltd
 688180.SS :
    * PHASE III CLINICAL STUDY OF TORIPALIMAB IN COMBINATION
WITH
BEVACIZUMAB MET PRIMARY ENDPOINT


Further company coverage:  688180.SS 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Shanghai Junshi Biosciences

    See all news